Health Care·Biotechnology·$5.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.67 | N/A | +62.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.67 | N/A | +62.14% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions impacting future performance. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Despite beating EPS expectations significantly, Apellis Pharmaceutical's stock dropped by over 31% in reaction to the earnings report. The lack of revenue data and forward guidance contributed to investor uncertainty. Management's defensive tone suggests that the company is facing challenges that could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Oct 27, 2025